Evrenzo (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients
Product Information |
|
PRODUCT NAME |
Evrenzo??Tablets?20mg Evrenzo??Tablets 50mg Evrenzo??Tablets 100mg |
GENERAL NAME |
Roxadustat |
INDICATIONS |
Renal anemia in patients on dialysis |
DOSAGE AND ADMINISTRATION |
Patients not on erythropoiesis-stimulating agent treatment. For adults, the usual dosage is 50mg, the starting dose, as roxadustat orally administered three times weekly. The dosage thereafter should be adjusted according to the patient's condition; however, the maximum dose should not exceed 3.0mg/kg. ? Patients switching from erythropoiesis-stimulating agents. For adults, the usual dosage is 70 or 100mg, the starting dose, as roxadustat orally administered three times weekly. The dosage thereafter should be adjusted according to the patient's condition; however, the maximum dose should not exceed 3.0mg/kg. |
APPROVAL DATE |
September 20, 2019 ? |